JANX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Janux Therapeutics Inc (JANX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators show a bearish trend, and there are no recent positive catalysts or strong trading signals to suggest immediate upside potential. The financial performance, while showing some improvement in net income and EPS, remains negative overall. Analysts have been lowering price targets, and both hedge funds and insiders are selling, indicating a lack of confidence in the stock's near-term performance.
The MACD is below zero and negatively expanding, indicating bearish momentum. RSI is neutral at 41.176, showing no clear signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading below the pivot level of 13.901, with key support at 13.525 and resistance at 14.277.
NULL. There are no recent news updates or significant positive developments for the company.
Hedge funds and insiders are selling significantly, with hedge fund selling up 575.67% and insider selling up 137.72%. Analysts have been lowering price targets across the board, citing competitive pressures and platform risks. No recent congress trading data or influential figure activity to suggest confidence in the stock.
In Q4 2025, revenue remained at 0 with no growth. Net income improved by 58.02% YoY but remains negative at -$31.95M. EPS increased by 41.67% YoY to -0.51, but still in the negative range. Gross margin stayed at 100%, but this is not meaningful given the lack of revenue.
Analysts have been lowering price targets consistently. Truist reduced its target to $80 from $100, Cantor Fitzgerald to $100 from $150, and Guggenheim to $68 from $72, all while maintaining Buy or Overweight ratings. However, Clear Street downgraded the stock to Hold with a $12 target, citing platform risks and competitive challenges.
